慢性乙型肝炎药物治疗研究若干新进展  

New advances in drug therapy of chronic hepatitis B infection

作　　者：郑旸 何剑琴[1] 李兰娟[1] Zheng Yang;He Jianqin;Li Latyuan(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,the FirstAffiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003)

机构地区：[1]浙江大学医学院附属第一医院传染病诊治国家重点实验室国家感染性疾病临床医学研究中心感染性疾病诊治协同创新中心,杭州310003

出　　处：《中华临床感染病杂志》2019年第5期393-400,共8页Chinese Journal of Clinical Infectious Diseases

摘　　要：核昔(酸)类药物和干扰素是目前治疗慢性乙型病毒性肝炎的主要药物,虽可持续抑制HBV DNA,但仍无法有效地清除HBsAgo随着对HBV生活史研究的深入和全新的直接抗病毒药物在丙型肝炎治疗上的突破,多种旨在“治愈乙型肝炎”、清除HBsAg的新药正处在临床试验或研发中。本文就慢性乙型肝炎新药的最新研究进展作一综述。Nucleos(t)ide analogs and interferon are currently the main drugs for the treatment of chronic hepatitis B;they can induce sustained virologic suppression of HBV DNA,but still can’t clear HBsAg effectively.With the further understanding of the biology and life cycle of HBV and the breakthrough of direct antiviral agent for HCV treatment,multiple new drugs aiming at"cure HBV"and clear HBsAg are undergoing preclinical development and/or clinical trials.This article reviews the latest advances in drug therapy of chronic hepatitis B infection.

关 键 词：肝炎 乙型 慢性 抗病毒药 直接抗病毒药物 免疫治疗 

分 类 号：R[医药卫生]